Staphylococcus aureus bacteremia: Difference between revisions

From IDWiki
Staphylococcus aureus bacteremia
No edit summary
No edit summary
Line 16: Line 16:
 
*May have back pain unrelated to spinal osteomyelitis
 
*May have back pain unrelated to spinal osteomyelitis
 
*May present with focus of metastatic disease
 
*May present with focus of metastatic disease
  +
*Associated with about 30% mortality[[CiteRef::bai2022st]]
   
 
==Investigations==
 
==Investigations==
Line 30: Line 31:
 
***Injection drug use
 
***Injection drug use
 
***Persistent bacteremia beyond 72 hours
 
***Persistent bacteremia beyond 72 hours
**Can also use [[PREDICT score]] to decide if they need TEE
+
**Can also use [[PREDICT score]] to decide if they need TEE[[CiteRef::palraj2015pr]]
  +
**Can also use [[VIRSTA score]] to decide if they need TEE[[CiteRef::tubiana2016th]]
   
 
==Management==
 
==Management==

Revision as of 11:04, 15 April 2022

Background

Classification

  • Community-onset: positive blood culture obtained within 48 hours of presentation
  • Nosocomial: positive blood culture obtained after 48 hours of presentation

Etiology

  • IVDU
  • Poor dentition
  • Dental work

Clinical Manifestations

  • Often non-specific fevers and chills, diagnosed on blood cultures
  • May have back pain unrelated to spinal osteomyelitis
  • May present with focus of metastatic disease
  • Associated with about 30% mortality1

Investigations

Management

  • Infectious diseases consultation
  • Must rule out endocarditis! TTE, followed by TEE if suspicion remains high (see PREDICT score)
    • Low risk for endocarditis (no TEE) if all of the following:
      • No intracardiac device
      • Sterile follow-up blood cultures within 4 days from the initial set
      • No hemodialysis
      • Nosocomial acquisition
      • Absence of secondary foci
      • No clinical signs of endocarditis
    • Uncomplicated if all of the following:
      • Endocarditis is excluded
      • No implanted prostheses
      • Blood cultures clear by 2-4 days
      • Defervesces within 72 hours
      • No evidence of metastases
      • +/- identified source has been removed
  • Two-week course acceptable if uncomplicated, otherwise 4-6 weeks
  • MSSA: cloxacillin 2g IV q4h for 2 weeks (cefazolin as an alternative)
  • MRSA: vancomycin 1g IV q12h for 2 weeks
    • Adjust based on serum trough before every fourth dose
    • Target trough 15-20

Prognosis

  • Mortality 20-50% at 30 days, 60% at 1 year
  • Mortality halved by ID consult
  • Prognosis worse with
    • Increased age
    • Female sex
    • Pneumonia or source unknown
    • Dementia
    • Increasing comorbidities
    • Shock at time of presentation
    • Institutionalized patient

Further Reading

References

  1. ^  Anthony D. Bai, Carson KL. Lo, Adam S. Komorowski, Mallika Suresh, Kevin Guo, Akhil Garg, Pranav Tandon, Julien Senecal, Olivier Del Corpo, Isabella Stefanova, Clare Fogarty, Guillaume Butler-Laporte, Emily G. McDonald, Matthew P. Cheng, Andrew M. Morris, Mark Loeb, Todd C. Lee. Staphylococcus aureus bacteremia mortality: A systematic review and meta-analysis. Clinical Microbiology and Infection. 2022. doi:10.1016/j.cmi.2022.03.015.
  2. ^  Bharath Raj Palraj, Larry M. Baddour, Erik P. Hess, James M. Steckelberg, Walter R. Wilson, Brian D. Lahr, M. Rizwan Sohail. Predicting Risk of Endocarditis Using a Clinical Tool (PREDICT): Scoring System to Guide Use of Echocardiography in the Management of Staphylococcus aureus Bacteremia. Clinical Infectious Diseases. 2015;61(1):18-28. doi:10.1093/cid/civ235.
  3. ^  Sarah Tubiana, Xavier Duval, François Alla, Christine Selton-Suty, Pierre Tattevin, François Delahaye, Lionel Piroth, Catherine Chirouze, Jean-Philippe Lavigne, Marie-Line Erpelding, Bruno Hoen, François Vandenesch, Bernard Iung, Vincent Le Moing. The VIRSTA score, a prediction score to estimate risk of infective endocarditis and determine priority for echocardiography in patients with Staphylococcus aureus bacteremia. Journal of Infection. 2016;72(5):544-553. doi:10.1016/j.jinf.2016.02.003.